Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma

First-line cancer therapies such as alkylating agents and radiation have limited survival benefits for Glioblastoma (GBM) patients. Current research strongly supports the notion that inhibition of aberrant tumor metabolism holds promise as a therapeutic strategy when used in combination with radiati...

Descripción completa

Detalles Bibliográficos
Autores principales: Vartanian, Alenoush, Agnihotri, Sameer, Wilson, Mark R., Burrell, Kelly E., Tonge, Peter D., Alamsahebpour, Amir, Jalali, Shahrzad, Taccone, Michael S., Mansouri, Sheila, Golbourn, Brian, Aldape, Kenneth D., Zadeh, Gelareh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342495/
https://www.ncbi.nlm.nih.gov/pubmed/27588472
http://dx.doi.org/10.18632/oncotarget.11680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342495/
https://www.ncbi.nlm.nih.gov/pubmed/27588472
http://dx.doi.org/10.18632/oncotarget.11680

Ejemplares similares